Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.
Authors: Ayas M,  Eapen M,  Le-Rademacher J,  Carreras J,  Abdel-Azim H,  Alter BP,  Anderlini P,  Battiwalla M,  Bierings M,  Buchbinder DK,  Bonfim C,  Camitta BM,  Fasth AL,  Gale RP,  Lee MA,  Lund TC,  Myers KC,  Olsson RF,  Page KM,  Prestidge TD,  Radhi M,  Shah AJ,  Schultz KR,  Wirk B,  Wagner JE,  Deeg HJ
Journal: Biol Blood Marrow Transplant
Date: 2015 Oct
Branches: CGB
PubMed ID: 26116087
PMC ID: PMC4568139
Abstract: A second allogeneic hematopoietic cell transplantation (HCT) is the sole salvage option for individuals who develop graft failure after their first HCT. Data on outcomes after second HCT in patients with Fanconi anemia (FA) are scarce. Here we report outcomes after second allogeneic HCT for FA (n = 81). The indication for second HCT was graft failure after the first HCT. Transplantations were performed between 1990 and 2012. The timing of the second HCT predicted subsequent graft failure and survival. Graft failure was high when the second HCT was performed less than 3 months from the first. The 3-month probability of graft failure was 69% when the interval between the first HCT and second HCT was less than 3 months, compared with 23% when the interval was longer (P < .001). Consequently, the 1-year survival rate was substantially lower when the interval between the first and second HCTs was less than 3 months compared with longer (23% vs 58%; P = .001). The corresponding 5-year probability of survival was 16% and 45%, respectively (P = .006). Taken together, these data suggest that fewer than one-half of patients with FA undergoing a second HCT for graft failure are long-term survivors. There is an urgent need to develop strategies to reduce the rate of graft failure after first HCT.